lactic acid has been researched along with Syndrome in 56 studies
Lactic Acid: A normal intermediate in the fermentation (oxidation, metabolism) of sugar. The concentrated form is used internally to prevent gastrointestinal fermentation. (From Stedman, 26th ed)
2-hydroxypropanoic acid : A 2-hydroxy monocarboxylic acid that is propanoic acid in which one of the alpha-hydrogens is replaced by a hydroxy group.
Syndrome: A characteristic symptom complex.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Hand-foot syndrome (HFS) is a dose-limiting toxicity of capecitabine for which no effective preventative treatment has been definitively demonstrated." | 9.14 | Placebo-controlled trial to determine the effectiveness of a urea/lactic acid-based topical keratolytic agent for prevention of capecitabine-induced hand-foot syndrome: North Central Cancer Treatment Group Study N05C5. ( Berenberg, JL; Christian, D; Delaune, R; Loprinzi, CL; Menon, SP; Pajon, ER; Qin, R; Rowland, KM; Satele, DV; Thomas, S; Wolf, SL, 2010) |
| " We describe 2 children with SBS who we believe are the second and third patients documented to have experienced both D-lactic acidosis and urolithiasis." | 7.88 | Stoned-A Syndrome of D-Lactic Acidosis and Urolithiasis. ( Berman, CM; Merritt, RJ, 2018) |
| "Propofol infusion syndrome (PRIS) is a rare but frequently fatal condition." | 7.77 | Lactate-to-pyruvate ratio as a marker of propofol infusion syndrome after subarachnoid hemorrhage. ( Kumar, MA; Levine, JM; Pisapia, JM; Wendell, LC; Zager, EL, 2011) |
| "Pyruvate dehydrogenase complex (PDHC) activity was measured in cultured fibroblasts from 12 patients with Friedreich's ataxia (FA), and in 1 patient with lactic acidosis and ataxia." | 7.66 | Pyruvate-dehydrogenase complex in ataxic patients: enzyme deficiency in ataxic encephalopathy plus lactic acidosis and normal activity in Friedreich ataxia. ( Bottacchi, E; Cardace, G; Di Donato, S; Giovanardi-Rossi, P; Moschen, G; Uziel, G, 1982) |
| "The prevalence of prostatitis is extremely high, with vast majority belongs to National Institutes of Health Category III: Chronic Prostatitis (CP)/Chronic Pelvic Pain Syndromes (CPPS)." | 5.35 | Frequent ejaculation associated free radical and lactic acid accumulation cause noninfectious inflammation and muscle dysfunction: a potential mechanism for symptoms in Chronic Prostatitis/Chronic Pelvic Pain Syndrome. ( Chen, Q; Peng, H; Tan, Y, 2009) |
| "Hand-foot syndrome (HFS) is a dose-limiting toxicity of capecitabine for which no effective preventative treatment has been definitively demonstrated." | 5.14 | Placebo-controlled trial to determine the effectiveness of a urea/lactic acid-based topical keratolytic agent for prevention of capecitabine-induced hand-foot syndrome: North Central Cancer Treatment Group Study N05C5. ( Berenberg, JL; Christian, D; Delaune, R; Loprinzi, CL; Menon, SP; Pajon, ER; Qin, R; Rowland, KM; Satele, DV; Thomas, S; Wolf, SL, 2010) |
| " We describe 2 children with SBS who we believe are the second and third patients documented to have experienced both D-lactic acidosis and urolithiasis." | 3.88 | Stoned-A Syndrome of D-Lactic Acidosis and Urolithiasis. ( Berman, CM; Merritt, RJ, 2018) |
| "Propofol infusion syndrome (PRIS) is a rare but frequently fatal condition." | 3.77 | Lactate-to-pyruvate ratio as a marker of propofol infusion syndrome after subarachnoid hemorrhage. ( Kumar, MA; Levine, JM; Pisapia, JM; Wendell, LC; Zager, EL, 2011) |
| "Maternally inherited diabetes and deafness (MIDD) and myoencephalopathy, lactic acidosis, stroke-like episodes (MELAS) syndromes are characterized by the same A3243G mutation of mitochondrial DNA (mtDNA)." | 3.75 | Brain anomalies in maternally inherited diabetes and deafness syndrome. ( Cozzone, PJ; Felician, O; Fromont, I; Lebail, B; Lefur, Y; Mancini, J; Nicoli, F; Paquis-Flucklinger, V; Valéro, R; Vialettes, B, 2009) |
| " This association is suggestive of the MIDD syndrome and the demonstration of metabolic abnormalities (raised serum lactic acid, abnormal lactate/pyruvate ratio) was compatible with a mitochondrial disease." | 3.74 | [Dilated cardiomyopathy, diabetes and deafness related to a mutation of mitochondrial DNA]. ( Charbonnier, B; Ferreira-Maldent, N; Guilmot, JL; Maillot, F; Quilliet, L, 2007) |
| " Lactic acidosis, characterized by metabolic acidosis, blood lactate above 5 mmol/l, hepatic steatosis and high mortality, represents the extreme end of this spectrum where there is complete decompensation." | 3.71 | Hyperlactatemia syndromes in people with HIV infection. ( John, M; Mallal, S, 2002) |
| "Low muscle glycogen levels due to consecutive days of extensive exercise have been shown to cause fatigue and thus decrements in performance." | 3.70 | Overtraining and glycogen depletion hypothesis. ( Snyder, AC, 1998) |
| "We report a patient with mitochondrial myopathy, encephalopathy, lactic acidosis, and strokelike episodes who experienced visual and auditory hallucinations." | 3.68 | Therapeutic effect of sodium dichloroacetate on visual and auditory hallucinations in a patient with MELAS. ( Hashimoto, T; Ito, M; Kuroda, Y; Naito, E; Saijo, T; Takeda, E, 1991) |
| "Pyruvate dehydrogenase complex (PDHC) activity was measured in cultured fibroblasts from 12 patients with Friedreich's ataxia (FA), and in 1 patient with lactic acidosis and ataxia." | 3.66 | Pyruvate-dehydrogenase complex in ataxic patients: enzyme deficiency in ataxic encephalopathy plus lactic acidosis and normal activity in Friedreich ataxia. ( Bottacchi, E; Cardace, G; Di Donato, S; Giovanardi-Rossi, P; Moschen, G; Uziel, G, 1982) |
| "Manifestations suggestive of migraine were present in each child." | 2.40 | Mitochondrial disease and cyclic vomiting syndrome. ( Boles, RG; Williams, JC, 1999) |
| "Netherton's syndrome is a rare symptom complex characterized by greatly elevated IgE levels with atopic manifestations, an ichthyotic skin disorder (ichthyosis linearis circumflexa and/or congenital lamellar ichthyosis), and the characteristic hair abnormality trichorrhexis invaginata." | 2.39 | Netherton's syndrome: a syndrome of elevated IgE and characteristic skin and hair findings. ( deShazo, RD; Smith, DL; Smith, JG; Wong, SW, 1995) |
| "Despite treatment, this syndrome complicated the interpretation of blood glucose readings as a measure of islet graft function and resulted in death or the need for euthanasia in all seven animals." | 1.38 | A syndrome of severe hypoglycemia and acidosis in young immunosuppressed diabetic monkeys and pigs-association with sepsis. ( Bottino, R; Cooper, DK; Dons, EM; Echeverri, GJ; Rigatti, LH; van der Windt, DJ; Wagner, R; Wijkstrom, M; Zhou, H, 2012) |
| "Acute type A aortic dissection can be complicated by visceral malperfusion and is associated with a significant surgical morbidity and mortality." | 1.36 | Acute Complex Type A Dissection associated with peripheral malperfusion syndrome treated with a staged approach guided by lactate levels. ( Ashrafian, H; Athanasiou, T; Bicknell, C; Dialynas, M; Hamady, M; Mireskandari, M; Suliman, A, 2010) |
| "The prevalence of prostatitis is extremely high, with vast majority belongs to National Institutes of Health Category III: Chronic Prostatitis (CP)/Chronic Pelvic Pain Syndromes (CPPS)." | 1.35 | Frequent ejaculation associated free radical and lactic acid accumulation cause noninfectious inflammation and muscle dysfunction: a potential mechanism for symptoms in Chronic Prostatitis/Chronic Pelvic Pain Syndrome. ( Chen, Q; Peng, H; Tan, Y, 2009) |
| "Eleven patients with syndromic craniosynostosis were treated with gradual distraction fronto-orbital advancement using "floating forehead." | 1.33 | Gradual distraction fronto-orbital advancement with 'floating forehead' for patients with syndromic craniosynostosis. ( Nagashima, T; Nishimoto, S; Oyama, T; Shimizu, F; Takeda, M; Toda, N; Tsugawa, T, 2006) |
| "PEHO syndrome is a rare symptom complex of severe progressive encephalopathy, edema, hypsarrhythmia, and optic atrophy." | 1.33 | Serial MR imaging, diffusion tensor imaging, and MR spectroscopic findings in a child with progressive encephalopathy, edema, hypsarrhythmia, and optic atrophy (PEHO) syndrome. ( Boltshauser, E; Huisman, TA; Klein, A; Straube, T; Werner, B, 2006) |
| "Aicardi-Goutières syndrome is a rare progressive encephalopathy characterized by acquired microcephaly, basal ganglia calcification, and chronic CSF lymphocytosis, raised levels of interferon alpha in CSF and plasma and chill-blain type lesions." | 1.32 | Brain lactic alkalosis in Aicardi-Goutières syndrome. ( Battini, R; Bianchi, MC; Cheong, J; Cioni, G; Cowan, FM; Cox, IJ; Robertson, NJ; Stafler, P; Tosetti, M, 2004) |
| "This complex syndrome is associated with cyclosporine A therapy or a variety of other conditions in which blood pressure rises acutely." | 1.31 | Clinical spectrum of reversible posterior leukoencephalopathy syndrome. ( Koo, J; Kwon, S; Lee, S, 2001) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 12 (21.43) | 18.7374 |
| 1990's | 14 (25.00) | 18.2507 |
| 2000's | 19 (33.93) | 29.6817 |
| 2010's | 8 (14.29) | 24.3611 |
| 2020's | 3 (5.36) | 2.80 |
| Authors | Studies |
|---|---|
| Puledda, F | 1 |
| Ffytche, D | 1 |
| Lythgoe, DJ | 1 |
| O'Daly, O | 1 |
| Schankin, C | 1 |
| Williams, SCR | 1 |
| Goadsby, PJ | 1 |
| Zheng, Y | 1 |
| Liang, H | 1 |
| Li, Z | 1 |
| Tang, M | 1 |
| Song, L | 1 |
| Rauserova-Lexmaulova, L | 1 |
| Vanova-Uhrikova, I | 1 |
| Rehakova, K | 1 |
| Berman, CM | 1 |
| Merritt, RJ | 1 |
| Lance, S | 1 |
| Wong, G | 1 |
| ALTMANN, A | 1 |
| Peng, H | 1 |
| Chen, Q | 1 |
| Tan, Y | 1 |
| Fromont, I | 1 |
| Nicoli, F | 1 |
| Valéro, R | 1 |
| Felician, O | 1 |
| Lebail, B | 1 |
| Lefur, Y | 1 |
| Mancini, J | 1 |
| Paquis-Flucklinger, V | 1 |
| Cozzone, PJ | 1 |
| Vialettes, B | 1 |
| Pérez de Heredia, F | 1 |
| Wood, IS | 1 |
| Trayhurn, P | 1 |
| Suliman, A | 1 |
| Dialynas, M | 1 |
| Ashrafian, H | 1 |
| Bicknell, C | 1 |
| Mireskandari, M | 1 |
| Hamady, M | 1 |
| Athanasiou, T | 1 |
| Jun, HS | 1 |
| Lee, YM | 1 |
| Cheung, YY | 1 |
| McDermott, DH | 1 |
| Murphy, PM | 1 |
| De Ravin, SS | 1 |
| Mansfield, BC | 1 |
| Chou, JY | 1 |
| Wolf, SL | 1 |
| Qin, R | 1 |
| Menon, SP | 1 |
| Rowland, KM | 1 |
| Thomas, S | 1 |
| Delaune, R | 1 |
| Christian, D | 1 |
| Pajon, ER | 1 |
| Satele, DV | 1 |
| Berenberg, JL | 1 |
| Loprinzi, CL | 1 |
| Pisapia, JM | 1 |
| Wendell, LC | 1 |
| Kumar, MA | 1 |
| Zager, EL | 1 |
| Levine, JM | 1 |
| Zhou, H | 1 |
| van der Windt, DJ | 1 |
| Dons, EM | 1 |
| Rigatti, LH | 1 |
| Echeverri, GJ | 1 |
| Bottino, R | 1 |
| Wijkstrom, M | 1 |
| Wagner, R | 1 |
| Cooper, DK | 1 |
| Hoffman, TM | 1 |
| Wernovsky, G | 1 |
| Atz, AM | 1 |
| Kulik, TJ | 1 |
| Nelson, DP | 1 |
| Chang, AC | 1 |
| Bailey, JM | 1 |
| Akbary, A | 1 |
| Kocsis, JF | 1 |
| Kaczmarek, R | 1 |
| Spray, TL | 1 |
| Wessel, DL | 1 |
| ROYER, R | 1 |
| Spitzer, C | 1 |
| Foltys, H | 1 |
| Lemmen, SW | 1 |
| Block, F | 1 |
| Robertson, NJ | 1 |
| Stafler, P | 1 |
| Battini, R | 1 |
| Cheong, J | 1 |
| Tosetti, M | 1 |
| Bianchi, MC | 1 |
| Cox, IJ | 1 |
| Cowan, FM | 1 |
| Cioni, G | 1 |
| Nagae-Poetscher, LM | 1 |
| Bibat, G | 1 |
| Philippart, M | 2 |
| Rosemberg, S | 1 |
| Fatemi, A | 1 |
| Lacerda, MT | 1 |
| Costa, MO | 1 |
| Kok, F | 1 |
| Costa Leite, C | 1 |
| Horská, A | 1 |
| Barker, PB | 1 |
| Naidu, S | 1 |
| Barnérias, C | 1 |
| Giurgea, I | 1 |
| Hertz-Pannier, L | 1 |
| Bahi-Buisson, N | 1 |
| Boddaert, N | 1 |
| Rustin, P | 1 |
| Rotig, A | 1 |
| Desguerre, I | 1 |
| Munnich, A | 1 |
| de Lonlay, P | 1 |
| Nishimoto, S | 1 |
| Oyama, T | 1 |
| Nagashima, T | 1 |
| Shimizu, F | 1 |
| Tsugawa, T | 1 |
| Takeda, M | 1 |
| Toda, N | 1 |
| Huisman, TA | 1 |
| Klein, A | 1 |
| Werner, B | 1 |
| Straube, T | 1 |
| Boltshauser, E | 1 |
| Sperl, W | 1 |
| Jesina, P | 1 |
| Zeman, J | 1 |
| Mayr, JA | 1 |
| Demeirleir, L | 1 |
| VanCoster, R | 1 |
| Pícková, A | 1 |
| Hansíková, H | 1 |
| Houst'ková, H | 1 |
| Krejcík, Z | 1 |
| Koch, J | 1 |
| Smet, J | 1 |
| Muss, W | 1 |
| Holme, E | 1 |
| Houstek, J | 1 |
| Walia, A | 1 |
| Thapa, BR | 1 |
| Kim, V | 1 |
| Ferreira-Maldent, N | 1 |
| Maillot, F | 1 |
| Quilliet, L | 1 |
| Guilmot, JL | 1 |
| Charbonnier, B | 1 |
| Luo, HG | 1 |
| Ding, J | 1 |
| Yue, GX | 1 |
| Chen, JX | 1 |
| Lössner, J | 1 |
| Lehmann, W | 1 |
| Kühn, HJ | 1 |
| Ziegan, J | 1 |
| Brehme, M | 1 |
| Livingstone, IR | 1 |
| Gardner-Medwin, D | 1 |
| Pennington, RJ | 1 |
| Uziel, G | 1 |
| Bottacchi, E | 1 |
| Moschen, G | 1 |
| Giovanardi-Rossi, P | 1 |
| Cardace, G | 1 |
| Di Donato, S | 1 |
| Tsuchiyama, A | 1 |
| Oyanagi, K | 1 |
| Sogawa, H | 1 |
| Nakao, T | 1 |
| Ogawa, K | 1 |
| Fujita, S | 1 |
| Bannister, DW | 1 |
| O'Neill, IE | 1 |
| Whitehead, CC | 1 |
| Smith, DL | 2 |
| Smith, JG | 2 |
| Wong, SW | 2 |
| deShazo, RD | 2 |
| Flynn, TW | 1 |
| Connery, SM | 1 |
| Smutok, MA | 1 |
| Zeballos, RJ | 1 |
| Weisman, IM | 1 |
| Vallet, B | 1 |
| Chopin, C | 1 |
| Curtis, SE | 1 |
| Dupuis, BA | 1 |
| Fourrier, F | 1 |
| Mehdaoui, H | 1 |
| LeRoy, B | 1 |
| Rime, A | 1 |
| Santre, C | 1 |
| Herbecq, P | 1 |
| Joynt, G | 1 |
| Doedens, L | 1 |
| Lipman, J | 1 |
| Bothma, P | 1 |
| Campistol, J | 1 |
| García-García, JJ | 1 |
| Lobera, E | 1 |
| Sanmartí, FX | 1 |
| Conill, J | 1 |
| Fernández-Alvarez, E | 1 |
| Morris, AA | 1 |
| Lamont, PJ | 1 |
| Clayton, PT | 1 |
| Snyder, AC | 1 |
| Foster, C | 1 |
| Boles, RG | 1 |
| Williams, JC | 1 |
| Hill, BD | 1 |
| McManus, AC | 1 |
| Brown, NN | 1 |
| Playford, CL | 1 |
| Noble, JW | 1 |
| Vanuxem, P | 1 |
| Vanuxem, D | 1 |
| Raharison, L | 1 |
| Aubert, M | 1 |
| Pouliquen, G | 1 |
| Deslangles, O | 1 |
| Kwon, S | 1 |
| Koo, J | 1 |
| Lee, S | 1 |
| John, M | 1 |
| Mallal, S | 1 |
| Guglielminotti, J | 1 |
| Pernet, P | 1 |
| Maury, E | 1 |
| Alzieu, M | 1 |
| Vaubourdolle, M | 1 |
| Guidet, B | 1 |
| Offenstadt, G | 1 |
| Imataka, G | 1 |
| Yamanouchi, H | 1 |
| Thomassen, A | 1 |
| Nielsen, TT | 1 |
| Bagger, JP | 1 |
| Pedersen, AK | 1 |
| Henningsen, P | 1 |
| Abe, K | 1 |
| Fujimura, H | 1 |
| Nishikawa, Y | 1 |
| Yorifuji, S | 1 |
| Mezaki, T | 1 |
| Hirono, N | 1 |
| Nishitani, N | 1 |
| Kameyama, M | 1 |
| van Hellenberg Hubar, JL | 1 |
| Gabreëls, FJ | 1 |
| Ruitenbeek, W | 1 |
| Sengers, RC | 1 |
| Renier, WO | 1 |
| Thijssen, HO | 1 |
| ter Laak, HJ | 1 |
| Saijo, T | 1 |
| Naito, E | 1 |
| Ito, M | 1 |
| Takeda, E | 1 |
| Hashimoto, T | 1 |
| Kuroda, Y | 1 |
| Haas, RH | 1 |
| Rice, MA | 1 |
| Trauner, DA | 1 |
| Merritt, TA | 1 |
| Kobayashi, M | 1 |
| Morishita, H | 1 |
| Sugiyama, N | 1 |
| Yokochi, K | 1 |
| Nakano, M | 1 |
| Wada, Y | 1 |
| Hotta, Y | 1 |
| Terauchi, A | 1 |
| Nonaka, I | 1 |
| Al-Mateen, M | 1 |
| Shields, WD | 1 |
| Beverley, DW | 1 |
| Wheeler, D | 1 |
| Cannon, RO | 1 |
| Leon, MB | 1 |
| Watson, RM | 1 |
| Rosing, DR | 1 |
| Epstein, SE | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Phase II, Randomised Controlled Trial to Evaluate the Efficacy and Safety of Moisturising Creams With or Without Palm-oil-derived Vitamin E Concentrate in Addition to Urea-based Cream or Urea-based Cream Alone in Capecitabine-associated Palmar-Plantar E[NCT05939726] | 90 participants (Anticipated) | Interventional | 2023-05-16 | Recruiting | |||
| A Phase III Randomized, Placebo-controlled, Double-blind Trial to Determine the Effectiveness of a Urea/Lactic Acid-Based Topical Keratolytic Agent and Vitamin B-6 for Prevention of Capecitabine-Induced Hand and Foot Syndrome[NCT00296036] | Phase 3 | 137 participants (Actual) | Interventional | 2006-06-30 | Completed | ||
| STeroids to REduce Systemic Inflammation After Infant Heart Surgery (STRESS)[NCT03229538] | Phase 3 | 1,263 participants (Actual) | Interventional | 2017-10-18 | Completed | ||
| Phase 2 Prospective, Randomized, Double-Blind Pilot Study on Cardiac Output Following Corrective Open Heart Surgery in Children Less Than One Year: Use of Levosimendan Versus Milrinone.[NCT00549107] | Phase 2 | 40 participants (Anticipated) | Interventional | 2007-09-30 | Recruiting | ||
| Preoperative Corticosteroid Therapy in Neonates Undergoing Cardiopulmonary Bypass[NCT00934843] | 77 participants (Actual) | Interventional | 2007-03-31 | Completed | |||
| Use of the Cardioprotectant Dexrazoxane During Congenital Heart Surgery: Proposal for Pilot Investigation[NCT02519335] | Phase 1 | 12 participants (Actual) | Interventional | 2014-09-30 | Terminated (stopped due to PI no longer at this facility) | ||
| 2- Inhaled Milrinone Prevents the Increase in Pulmonary Artery Pressure After CPB[NCT00819377] | Phase 2 | 124 participants (Anticipated) | Interventional | 2009-02-28 | Completed | ||
| Use of the Cardioprotectant Dexrazoxane During Congenital Heart Surgery[NCT04997291] | Phase 1 | 12 participants (Anticipated) | Interventional | 2021-04-09 | Recruiting | ||
| Effects of Insertion of Diaphragmatic Breathing Exercises, Cardiorespiratory and Strength Exercises, and Cooperative Sports Activities During Physical Education Classes on Anxiety and Depression Symptoms in Adolescents[NCT05561192] | 320 participants (Anticipated) | Interventional | 2023-02-01 | Not yet recruiting | |||
| Effects of Including 30-s Sprints During Low-intensity Cycling Exercises During a Training Camp on Performance and Muscle/Blood Characterisitcs[NCT04640883] | 18 participants (Actual) | Interventional | 2017-10-23 | Completed | |||
| Mitochondrial Energy Metabolism in Obese Women Undergoing Concurrent Physical Training[NCT03119350] | 14 participants (Actual) | Interventional | 2016-04-01 | Completed | |||
| Effects of Photobiomodulation and Deep Water Running Training in Subjects With Low Back Pain: a Randomized Controlled Trial[NCT03465228] | 54 participants (Actual) | Interventional | 2017-11-15 | Completed | |||
| Phase III Study of Intravenous Glutamate Infusion for Metabolic Protection of the Heart in Surgery for Unstable Coronary Artery Disease[NCT00489827] | Phase 3 | 865 participants (Actual) | Interventional | 2005-10-31 | Completed | ||
| Phase 3 Trial of Coenzyme Q10 in Mitochondrial Disease[NCT00432744] | Phase 3 | 24 participants (Actual) | Interventional | 2007-01-31 | Completed | ||
| CORonary MICrovascular Angina (CorMicA): a Randomised, Controlled, Pilot Trial[NCT03193294] | 151 participants (Actual) | Interventional | 2016-11-07 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
A patient self-reported hand-foot syndrome (HFSD), also known as palmar-plantar erythrodysesthesia, was completed daily while applying the cream. Patients rated skin severity symptoms individually in their hands and in their feet. Definitions of symptoms, which were based on Common Terminology Criteria for Adverse Events (CTCAE) v3.0, were provided to patients. The number of patients reporting moderate to severe symptoms in either hands or feet were tabulated and percentages are reported. (NCT00296036)
Timeframe: First 3 weeks of treatment
| Intervention | percentage of participants (Number) |
|---|---|
| Urea/Lactic Acid Cream | 13.6 |
| Placebo Cream | 10.2 |
Frequency and severity of adverse events reported by patients in weekly diary and evaluated through clinical assessment by NCI CTCAE v3.0. The number of patients reporting grade 3 or higher events are reported in this outcome measure. For a full list of all events, please refer to the Adverse Events section of this report. (NCT00296036)
Timeframe: Up to 4, 21-day cycles
| Intervention | participants (Number) | |
|---|---|---|
| Grade 3+ Adverse Event | Grade 4+ Adverse Event | |
| Placebo Cream | 18 | 3 |
| Urea/Lactic Acid Cream | 21 | 3 |
Calculated as discharge date minus surgery date. (NCT03229538)
Timeframe: Until hospital discharge, up to 4 months
| Intervention | Participants (Count of Participants) |
|---|---|
| Methylprednisolone Arm | 18 |
| Placebo Arm | 29 |
(NCT03229538)
Timeframe: Until hospital discharge, up to 4 months
| Intervention | Participants (Count of Participants) |
|---|---|
| Methylprednisolone Arm | 237 |
| Placebo Arm | 264 |
The 7 highest global ranking categories range from 91 (postoperative length of hospital stay > 90 days) to 97 (operative mortality). (NCT03229538)
Timeframe: Until hospital discharge, up to 4 months
| Intervention | Participants (Count of Participants) |
|---|---|
| Methylprednisolone Arm | 103 |
| Placebo Arm | 122 |
(NCT03229538)
Timeframe: up to 30 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Methylprednisolone Arm | 12 |
| Placebo Arm | 17 |
(NCT03229538)
Timeframe: Until hospital discharge, up to 4 months
| Intervention | Participants (Count of Participants) |
|---|---|
| Methylprednisolone Arm | 31 |
| Placebo Arm | 24 |
"Based upon the STS-CHSD registry defined cardiac dysfunction resulting in low cardiac output complication variable." (NCT03229538)
Timeframe: Until hospital discharge, up to 4 months
| Intervention | Participants (Count of Participants) |
|---|---|
| Methylprednisolone Arm | 31 |
| Placebo Arm | 37 |
(NCT03229538)
Timeframe: Until hospital discharge, up to 4 months
| Intervention | Participants (Count of Participants) |
|---|---|
| Methylprednisolone Arm | 41 |
| Placebo Arm | 51 |
The inotropic score was calculated by the equation using drug dosages in micrograms/kg/min, (dopamine+dobutamine) + (milrinonex10) + (epinephrinex100) and recorded hourly upon arrival to the ICUthrough 36 hours postoperatively. The highest score during this timeframe was recorded. This score converts dosages of commonly used inotropic medications into a score. The higher the score the more inotropic medications required. The minimum score would be zero indicating no inotropic medications were used. There is no maximum score. (NCT00934843)
Timeframe: over the first 36 hours after surgery
| Intervention | Scores on a scale (Mean) |
|---|---|
| MP Single Dose | 14.4 |
| MP Two Dose | 15.0 |
Number of participants who died of any cause between 36 hours and 30 days following cardiac surgery (NCT00934843)
Timeframe: at 36 hours and 30 days
| Intervention | participants (Number) |
|---|---|
| MP Single Dose | 1 |
| MP Two Dose | 0 |
The presence of low cardiac output syndrome (LCOS) was defined by the same definition used in the PRIMACORP study (Hoffman TM.et.al. Circulation 2003 107:996-1002). Specifically, if there were clinical signs and symptoms of low cardiac output (e.g., tachycardia, oliguria, cold extremities, cardiac arrest, etc.) which required one or more of the following interventions: mechanical circulatory support, the escalation of existing pharmacological circulatory support to >100% over baseline, or the initiation of new pharmacological circulatory support. (NCT00934843)
Timeframe: 36 hours
| Intervention | participants (Number) |
|---|---|
| MP Single Dose | 17 |
| MP Two Dose | 15 |
Total urine output in mL over the first 36 hours after cardiac surgery (NCT00934843)
Timeframe: over 36 hours
| Intervention | mL (Mean) |
|---|---|
| MP Single Dose | 498 |
| MP Two Dose | 453 |
Total amount of all fluids in and out during the first 36 hours postoperatively in mL. (NCT00934843)
Timeframe: over 36 hours
| Intervention | mL (Mean) | |
|---|---|---|
| Total Fluid in at 36 hr | Total Fluid out at 36 hr | |
| MP Single Dose | 575 | 600 |
| MP Two Dose | 586 | 558 |
Number of patients with atrial fibrillation recorded postoperatively (NCT00489827)
Timeframe: Hospital stay
| Intervention | Participants (Count of Participants) |
|---|---|
| Intravenous Glutamate | 147 |
| Saline Infusion | 152 |
ICU duration of stay (hours) (NCT00489827)
Timeframe: ICU stay
| Intervention | hours (Median) |
|---|---|
| Intravenous Glutamate | 21 |
| Saline Infusion | 21 |
(NCT00489827)
Timeframe: 30 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Intravenous Glutamate | 31 |
| Saline Infusion | 25 |
Incidence of Postoperative stroke < 24 hours of surgery verifed by CT-scan (NCT00489827)
Timeframe: 24 hours
| Intervention | Participants (Count of Participants) |
|---|---|
| Intravenous Glutamate | 4 |
| Saline Infusion | 6 |
Hemodynamic instability despite inotropes or need for IABP at the end of surgery in patients with severely reduced left ventricular ejection fraction (LVEF<0.40) (NCT00489827)
Timeframe: End of surgery
| Intervention | Participants (Count of Participants) |
|---|---|
| Intravenous Glutamate | 1 |
| Saline Infusion | 5 |
maximum p-creatinine value recorded postoperatively < 30 days (NCT00489827)
Timeframe: 30 days
| Intervention | µmol/L (Mean) |
|---|---|
| Intravenous Glutamate | 106 |
| Saline Infusion | 106 |
Severe circulatory failure according to prespecified criteria as judged by a blinded endpoints committee in CCS class IV patients (NCT00489827)
Timeframe: 30 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Intravenous Glutamate | 3 |
| Saline Infusion | 16 |
p-CK-MB postoperative day 1, p-troponin-T postoperative day 3 (NCT00489827)
Timeframe: perioperative
| Intervention | µg/L (Median) | |
|---|---|---|
| CK-MB day 1 | Troponin-T day 3 | |
| Intravenous Glutamate | 14 | 0.27 |
| Saline Infusion | 14 | 0.24 |
Mixed venous oxygen saturation (SvO2) measured at weaning from cardiopulmonary bypass and on arrival to ICU (NCT00489827)
Timeframe: Until arrival to ICU
| Intervention | percentage of saturated hemoglobin (Mean) | |
|---|---|---|
| SvO2 at weaning from CPB | SvO2 on arrival to ICU | |
| Intravenous Glutamate | 72.0 | 65.0 |
| Saline Infusion | 72.2 | 64.9 |
The McMaster Gross Motor Function is a validated scale ranging from 0 to 100 (the higher the better). Since there was the possibility of a subject becoming totally disabled our FDA peer reviewed design called for its use as follows: If the subject completed both periods, the score was calculated as the difference in scores between the end of Period 2 (at 12 months) minus that at the end of Period 1 (6 months). If a subject became totally disabled, this difference was considered as plus infinity if it occurred in period 1 (Penalizes period 1), and minus infinity if it occurred in Period 2 (Penalizes period 2). The two treatments were compared via the Wilcoxon test, and the effect size was estimated using Kendall's Tau-B. This is interpreted in a similar manner to correlation with positive values favoring COQenzyme10 and negative values favoring placebo. One of the links in this report is to the the GMFM scale and how it is scored. A link to the instrument is included. (NCT00432744)
Timeframe: Taken at 6 and 12 Months
| Intervention | units on a scale (Median) |
|---|---|
| Placebo First | -0.002 |
| CoenzymeQ10 Frist | -0.12 |
This is a multivariate analysis of the first two outcomes: Period 2 minus Period 1 GMFM88 and Peds Quality of Life, analyzed as follows: First, to be in the analysis, subjects must contribute at least one of these endpoints. Second, if the subject became totally disabled during period 1, the difference was defined as + infinity, (highest possible evidence favoring period 2), and if the subject became totally disabled in period 2, the subject was scored as - infinity (highest possible evidence favoring period 1). Period 2 minus period 1 differences were ranked form low to high with missing values scores at the mid-rank. The Hotelling T-square was computed on these ranks and the P-value was obtained from 100,000 rerandomizations as the fraction of rerandomizations with T-sq at least as large as that observed. (NCT00432744)
Timeframe: end of 12 month minus end of 6 month difference.
| Intervention | participants (Number) |
|---|---|
| Placebo First | 7 |
| CoenzymeQ10 Frist | 8 |
"The Pediatric Quality of Life Scale is a validated scale ranging from 0 to 100 (the higher the better). Since there was the possibility of a subject becoming totally disabled our FDA peer reviewed design called for its use as follows: If the subject completed both periods, the score was calculated as the difference in scores between the end of Period 2 (at 12 months) minus that at the end of Period 1 (6 months). If a subject became totally disabled, this difference was considered as plus infinity if it occurred in period 1 (Penalizes period 1), and minus infinity if it occurred in Period 2 (Penalizes period 2). The two treatments were compared via the Wilcoxon test, and the effect size was estimated using Kendall's Tau-B. This is interpreted in a similar manner to correlation with positive values favoring COQenzyme10 and negative values favoring placebo. Goggle pedsQL and Mapi to browse the copyrighted manual. A link to the instrument is included." (NCT00432744)
Timeframe: At 6 and 12 Months
| Intervention | units on a scale (Median) |
|---|---|
| Placebo First | -1.1 |
| CoenzymeQ10 Frist | -11.9 |
5 reviews available for lactic acid and Syndrome
| Article | Year |
|---|---|
[Bacterial meningitis as a complication of Fusobacterium necroforum infection in adults].
Topics: Adult; Anti-Bacterial Agents; Blood Glucose; Cerebrospinal Fluid Proteins; Diagnosis, Differential; | 2003 |
Netherton's syndrome: a syndrome of elevated IgE and characteristic skin and hair findings.
Topics: Biopsy, Needle; Child, Preschool; Diagnosis, Differential; Drug Therapy, Combination; Hair; Hair Dis | 1995 |
Mitochondrial disease and cyclic vomiting syndrome.
Topics: Adolescent; Adult; Child; Child, Preschool; DNA Mutational Analysis; DNA, Mitochondrial; Female; Hum | 1999 |
[Coenzyme Q10 deficiency].
Topics: Coenzymes; Diagnosis, Differential; Humans; Lactic Acid; Mitochondria; Mitochondrial Diseases; Mitoc | 2002 |
MELAS syndrome. Report of two patients, and comparison with data of 24 patients derived from the literature.
Topics: Biopsy; Child; Child, Preschool; Electroencephalography; Electromyography; Energy Metabolism; Enzyme | 1991 |
5 trials available for lactic acid and Syndrome
| Article | Year |
|---|---|
Placebo-controlled trial to determine the effectiveness of a urea/lactic acid-based topical keratolytic agent for prevention of capecitabine-induced hand-foot syndrome: North Central Cancer Treatment Group Study N05C5.
Topics: Administration, Topical; Antimetabolites, Antineoplastic; Capecitabine; Deoxycytidine; Double-Blind | 2010 |
Placebo-controlled trial to determine the effectiveness of a urea/lactic acid-based topical keratolytic agent for prevention of capecitabine-induced hand-foot syndrome: North Central Cancer Treatment Group Study N05C5.
Topics: Administration, Topical; Antimetabolites, Antineoplastic; Capecitabine; Deoxycytidine; Double-Blind | 2010 |
Placebo-controlled trial to determine the effectiveness of a urea/lactic acid-based topical keratolytic agent for prevention of capecitabine-induced hand-foot syndrome: North Central Cancer Treatment Group Study N05C5.
Topics: Administration, Topical; Antimetabolites, Antineoplastic; Capecitabine; Deoxycytidine; Double-Blind | 2010 |
Placebo-controlled trial to determine the effectiveness of a urea/lactic acid-based topical keratolytic agent for prevention of capecitabine-induced hand-foot syndrome: North Central Cancer Treatment Group Study N05C5.
Topics: Administration, Topical; Antimetabolites, Antineoplastic; Capecitabine; Deoxycytidine; Double-Blind | 2010 |
Efficacy and safety of milrinone in preventing low cardiac output syndrome in infants and children after corrective surgery for congenital heart disease.
Topics: Blood Pressure; Cardiac Output, Low; Child; Child, Preschool; Double-Blind Method; Endpoint Determin | 2003 |
Efficacy and safety of milrinone in preventing low cardiac output syndrome in infants and children after corrective surgery for congenital heart disease.
Topics: Blood Pressure; Cardiac Output, Low; Child; Child, Preschool; Double-Blind Method; Endpoint Determin | 2003 |
Efficacy and safety of milrinone in preventing low cardiac output syndrome in infants and children after corrective surgery for congenital heart disease.
Topics: Blood Pressure; Cardiac Output, Low; Child; Child, Preschool; Double-Blind Method; Endpoint Determin | 2003 |
Efficacy and safety of milrinone in preventing low cardiac output syndrome in infants and children after corrective surgery for congenital heart disease.
Topics: Blood Pressure; Cardiac Output, Low; Child; Child, Preschool; Double-Blind Method; Endpoint Determin | 2003 |
Efficacy and safety of milrinone in preventing low cardiac output syndrome in infants and children after corrective surgery for congenital heart disease.
Topics: Blood Pressure; Cardiac Output, Low; Child; Child, Preschool; Double-Blind Method; Endpoint Determin | 2003 |
Efficacy and safety of milrinone in preventing low cardiac output syndrome in infants and children after corrective surgery for congenital heart disease.
Topics: Blood Pressure; Cardiac Output, Low; Child; Child, Preschool; Double-Blind Method; Endpoint Determin | 2003 |
Efficacy and safety of milrinone in preventing low cardiac output syndrome in infants and children after corrective surgery for congenital heart disease.
Topics: Blood Pressure; Cardiac Output, Low; Child; Child, Preschool; Double-Blind Method; Endpoint Determin | 2003 |
Efficacy and safety of milrinone in preventing low cardiac output syndrome in infants and children after corrective surgery for congenital heart disease.
Topics: Blood Pressure; Cardiac Output, Low; Child; Child, Preschool; Double-Blind Method; Endpoint Determin | 2003 |
Efficacy and safety of milrinone in preventing low cardiac output syndrome in infants and children after corrective surgery for congenital heart disease.
Topics: Blood Pressure; Cardiac Output, Low; Child; Child, Preschool; Double-Blind Method; Endpoint Determin | 2003 |
Efficacy and safety of milrinone in preventing low cardiac output syndrome in infants and children after corrective surgery for congenital heart disease.
Topics: Blood Pressure; Cardiac Output, Low; Child; Child, Preschool; Double-Blind Method; Endpoint Determin | 2003 |
Efficacy and safety of milrinone in preventing low cardiac output syndrome in infants and children after corrective surgery for congenital heart disease.
Topics: Blood Pressure; Cardiac Output, Low; Child; Child, Preschool; Double-Blind Method; Endpoint Determin | 2003 |
Efficacy and safety of milrinone in preventing low cardiac output syndrome in infants and children after corrective surgery for congenital heart disease.
Topics: Blood Pressure; Cardiac Output, Low; Child; Child, Preschool; Double-Blind Method; Endpoint Determin | 2003 |
Efficacy and safety of milrinone in preventing low cardiac output syndrome in infants and children after corrective surgery for congenital heart disease.
Topics: Blood Pressure; Cardiac Output, Low; Child; Child, Preschool; Double-Blind Method; Endpoint Determin | 2003 |
Efficacy and safety of milrinone in preventing low cardiac output syndrome in infants and children after corrective surgery for congenital heart disease.
Topics: Blood Pressure; Cardiac Output, Low; Child; Child, Preschool; Double-Blind Method; Endpoint Determin | 2003 |
Efficacy and safety of milrinone in preventing low cardiac output syndrome in infants and children after corrective surgery for congenital heart disease.
Topics: Blood Pressure; Cardiac Output, Low; Child; Child, Preschool; Double-Blind Method; Endpoint Determin | 2003 |
Efficacy and safety of milrinone in preventing low cardiac output syndrome in infants and children after corrective surgery for congenital heart disease.
Topics: Blood Pressure; Cardiac Output, Low; Child; Child, Preschool; Double-Blind Method; Endpoint Determin | 2003 |
Efficacy and safety of milrinone in preventing low cardiac output syndrome in infants and children after corrective surgery for congenital heart disease.
Topics: Blood Pressure; Cardiac Output, Low; Child; Child, Preschool; Double-Blind Method; Endpoint Determin | 2003 |
Efficacy and safety of milrinone in preventing low cardiac output syndrome in infants and children after corrective surgery for congenital heart disease.
Topics: Blood Pressure; Cardiac Output, Low; Child; Child, Preschool; Double-Blind Method; Endpoint Determin | 2003 |
Efficacy and safety of milrinone in preventing low cardiac output syndrome in infants and children after corrective surgery for congenital heart disease.
Topics: Blood Pressure; Cardiac Output, Low; Child; Child, Preschool; Double-Blind Method; Endpoint Determin | 2003 |
Efficacy and safety of milrinone in preventing low cardiac output syndrome in infants and children after corrective surgery for congenital heart disease.
Topics: Blood Pressure; Cardiac Output, Low; Child; Child, Preschool; Double-Blind Method; Endpoint Determin | 2003 |
Efficacy and safety of milrinone in preventing low cardiac output syndrome in infants and children after corrective surgery for congenital heart disease.
Topics: Blood Pressure; Cardiac Output, Low; Child; Child, Preschool; Double-Blind Method; Endpoint Determin | 2003 |
Efficacy and safety of milrinone in preventing low cardiac output syndrome in infants and children after corrective surgery for congenital heart disease.
Topics: Blood Pressure; Cardiac Output, Low; Child; Child, Preschool; Double-Blind Method; Endpoint Determin | 2003 |
Efficacy and safety of milrinone in preventing low cardiac output syndrome in infants and children after corrective surgery for congenital heart disease.
Topics: Blood Pressure; Cardiac Output, Low; Child; Child, Preschool; Double-Blind Method; Endpoint Determin | 2003 |
Efficacy and safety of milrinone in preventing low cardiac output syndrome in infants and children after corrective surgery for congenital heart disease.
Topics: Blood Pressure; Cardiac Output, Low; Child; Child, Preschool; Double-Blind Method; Endpoint Determin | 2003 |
Efficacy and safety of milrinone in preventing low cardiac output syndrome in infants and children after corrective surgery for congenital heart disease.
Topics: Blood Pressure; Cardiac Output, Low; Child; Child, Preschool; Double-Blind Method; Endpoint Determin | 2003 |
Efficacy and safety of milrinone in preventing low cardiac output syndrome in infants and children after corrective surgery for congenital heart disease.
Topics: Blood Pressure; Cardiac Output, Low; Child; Child, Preschool; Double-Blind Method; Endpoint Determin | 2003 |
Efficacy and safety of milrinone in preventing low cardiac output syndrome in infants and children after corrective surgery for congenital heart disease.
Topics: Blood Pressure; Cardiac Output, Low; Child; Child, Preschool; Double-Blind Method; Endpoint Determin | 2003 |
Efficacy and safety of milrinone in preventing low cardiac output syndrome in infants and children after corrective surgery for congenital heart disease.
Topics: Blood Pressure; Cardiac Output, Low; Child; Child, Preschool; Double-Blind Method; Endpoint Determin | 2003 |
Efficacy and safety of milrinone in preventing low cardiac output syndrome in infants and children after corrective surgery for congenital heart disease.
Topics: Blood Pressure; Cardiac Output, Low; Child; Child, Preschool; Double-Blind Method; Endpoint Determin | 2003 |
Efficacy and safety of milrinone in preventing low cardiac output syndrome in infants and children after corrective surgery for congenital heart disease.
Topics: Blood Pressure; Cardiac Output, Low; Child; Child, Preschool; Double-Blind Method; Endpoint Determin | 2003 |
Efficacy and safety of milrinone in preventing low cardiac output syndrome in infants and children after corrective surgery for congenital heart disease.
Topics: Blood Pressure; Cardiac Output, Low; Child; Child, Preschool; Double-Blind Method; Endpoint Determin | 2003 |
Efficacy and safety of milrinone in preventing low cardiac output syndrome in infants and children after corrective surgery for congenital heart disease.
Topics: Blood Pressure; Cardiac Output, Low; Child; Child, Preschool; Double-Blind Method; Endpoint Determin | 2003 |
Efficacy and safety of milrinone in preventing low cardiac output syndrome in infants and children after corrective surgery for congenital heart disease.
Topics: Blood Pressure; Cardiac Output, Low; Child; Child, Preschool; Double-Blind Method; Endpoint Determin | 2003 |
Efficacy and safety of milrinone in preventing low cardiac output syndrome in infants and children after corrective surgery for congenital heart disease.
Topics: Blood Pressure; Cardiac Output, Low; Child; Child, Preschool; Double-Blind Method; Endpoint Determin | 2003 |
Efficacy and safety of milrinone in preventing low cardiac output syndrome in infants and children after corrective surgery for congenital heart disease.
Topics: Blood Pressure; Cardiac Output, Low; Child; Child, Preschool; Double-Blind Method; Endpoint Determin | 2003 |
Efficacy and safety of milrinone in preventing low cardiac output syndrome in infants and children after corrective surgery for congenital heart disease.
Topics: Blood Pressure; Cardiac Output, Low; Child; Child, Preschool; Double-Blind Method; Endpoint Determin | 2003 |
Prognostic value of the dobutamine test in patients with sepsis syndrome and normal lactate values: a prospective, multicenter study.
Topics: Adult; Aged; Critical Illness; Dobutamine; Female; Hemodynamics; Humans; Infusions, Intravenous; Lac | 1993 |
A bovine stress syndrome associated with exercise-induced hyperthermia.
Topics: Animals; Aspartate Aminotransferases; Bicarbonates; Blood Glucose; Body Temperature; Cattle; Cattle | 2000 |
Maximal exercise and muscle energy metabolism after recovery from exercise hyperthermia syndrome.
Topics: Adult; Blood Pressure; Body Temperature; Central Nervous System Diseases; Convalescence; Creatine Ki | 2001 |
46 other studies available for lactic acid and Syndrome
| Article | Year |
|---|---|
Insular and occipital changes in visual snow syndrome: a BOLD fMRI and MRS study.
Topics: Adult; Cerebral Cortex; Female; Functional Neuroimaging; Humans; Lactic Acid; Magnetic Resonance Ima | 2020 |
Skin microbiome in sensitive skin: The decrease of Staphylococcus epidermidis seems to be related to female lactic acid sting test sensitive skin.
Topics: Cosmetics; DNA, Bacterial; Female; Humans; Hyperesthesia; Lactic Acid; Microbiota; RNA, Ribosomal, 1 | 2020 |
Acid-Base, Electrolyte and Lactate Abnormalities as Well as Gastric Necrosis and Survival in Dogs With Gastric Dilation-Volvulus Syndrome. A Retrospective Study in 75 Dogs.
Topics: Animals; Czech Republic; Dog Diseases; Dogs; Electrolytes; Female; Gastric Dilatation; Hydrogen-Ion | 2020 |
Stoned-A Syndrome of D-Lactic Acidosis and Urolithiasis.
Topics: Acidosis, Lactic; Adolescent; Dysbiosis; Feces; Female; Gastrointestinal Microbiome; Humans; Infant; | 2018 |
Resorbable Construct for Subtotal Cranial Vault Remodeling.
Topics: Absorbable Implants; Craniosynostoses; Guided Tissue Regeneration; Humans; Infant; Lactic Acid; Male | 2016 |
The syndrome of malignant malnutrition (kwashiorkor; infantile pellagra) its conception as a protein deficiency and its treatment with skimmed lactic acid milk.
Topics: Animals; Dairy Products; Fertilization; Humans; Kwashiorkor; Lactic Acid; Milk; Nutrition Disorders; | 1948 |
Frequent ejaculation associated free radical and lactic acid accumulation cause noninfectious inflammation and muscle dysfunction: a potential mechanism for symptoms in Chronic Prostatitis/Chronic Pelvic Pain Syndrome.
Topics: Chronic Disease; Ejaculation; Free Radicals; Humans; Lactic Acid; Male; Models, Immunological; Myosi | 2009 |
Brain anomalies in maternally inherited diabetes and deafness syndrome.
Topics: Adult; Aged; Brain; Cerebellar Ataxia; Cognition Disorders; Deafness; Diabetes Mellitus; Diabetes Me | 2009 |
Hypoxia stimulates lactate release and modulates monocarboxylate transporter (MCT1, MCT2, and MCT4) expression in human adipocytes.
Topics: Adipocytes; Adipose Tissue; Antimutagenic Agents; Cells, Cultured; Cobalt; Female; Gene Expression R | 2010 |
Acute Complex Type A Dissection associated with peripheral malperfusion syndrome treated with a staged approach guided by lactate levels.
Topics: Aortic Aneurysm, Thoracic; Aortic Dissection; Biomarkers; Clinical Protocols; Femoral Artery; Humans | 2010 |
Lack of glucose recycling between endoplasmic reticulum and cytoplasm underlies cellular dysfunction in glucose-6-phosphatase-beta-deficient neutrophils in a congenital neutropenia syndrome.
Topics: Adenosine Triphosphate; Adolescent; Animals; Annexin A5; Apoptosis; Caspase 3; Child; Cytoplasm; End | 2010 |
Lactate-to-pyruvate ratio as a marker of propofol infusion syndrome after subarachnoid hemorrhage.
Topics: Adult; Biomarkers; Female; Humans; Hypnotics and Sedatives; Infusions, Intravenous; Lactic Acid; Pro | 2011 |
A syndrome of severe hypoglycemia and acidosis in young immunosuppressed diabetic monkeys and pigs-association with sepsis.
Topics: Acidosis; Animals; Bacteria; Blood Glucose; Diabetes Mellitus, Experimental; Disease Models, Animal; | 2012 |
[Findings on glucide metabolism in acute febrile confusional syndromes].
Topics: Confusion; Fever; Lactic Acid; Mental Disorders; Pyruvates; Syndrome | 1957 |
Brain lactic alkalosis in Aicardi-Goutières syndrome.
Topics: Alkalosis; Aspartic Acid; Basal Ganglia; Brain; Brain Diseases, Metabolic; Calcinosis; Creatinine; E | 2004 |
Leukoencephalopathy, cerebral calcifications, and cysts: new observations.
Topics: Adolescent; Aspartic Acid; Brain; Brain Diseases; Calcinosis; Central Nervous System Cysts; Child; C | 2004 |
Respiratory chain deficiency in a female with Aicardi-Goutières syndrome.
Topics: Basal Ganglia; Calcinosis; Chromatography, Gas; Dementia, Vascular; Female; Humans; Interferon-alpha | 2006 |
Gradual distraction fronto-orbital advancement with 'floating forehead' for patients with syndromic craniosynostosis.
Topics: Absorbable Implants; Bone Plates; Craniosynostoses; Dura Mater; Female; Follow-Up Studies; Forehead; | 2006 |
Serial MR imaging, diffusion tensor imaging, and MR spectroscopic findings in a child with progressive encephalopathy, edema, hypsarrhythmia, and optic atrophy (PEHO) syndrome.
Topics: Aspartic Acid; Atrophy; Brain Diseases; Brain Edema; Cerebellum; Child; Choline; Creatine; Diffusion | 2006 |
Deficiency of mitochondrial ATP synthase of nuclear genetic origin.
Topics: Adenosine Triphosphate; Adolescent; Age of Onset; Cardiomyopathy, Hypertrophic, Familial; Cell Nucle | 2006 |
Mitochondrial neuro-gastrointestinal encephalopathy syndrome.
Topics: Biopsy; Child; Diagnosis, Differential; Gastrointestinal Diseases; Humans; Intestinal Pseudo-Obstruc | 2006 |
[Dilated cardiomyopathy, diabetes and deafness related to a mutation of mitochondrial DNA].
Topics: Cardiomyopathy, Dilated; Deafness; Diabetes Mellitus; DNA, Mitochondrial; Female; Humans; Lactic Aci | 2007 |
[Metabonomic study of syndrome of liver qi stagnation and spleen deficiency in rats].
Topics: Acetic Acid; Animals; Diagnosis, Differential; Lactic Acid; Lipoproteins, LDL; Male; Medicine, Chine | 2007 |
[Ophthalmoplegia plus. On nosologic, biochemical, morphologic and computer tomographic aspects of the oculocraniosomatic syndrome].
Topics: Adult; Biopsy; Blepharoptosis; Brain Stem; Enzymes; Humans; Lactates; Lactic Acid; Male; Muscles; Ne | 1983 |
Familial intermittent ataxia with possible X-linked recessive inheritance. Two patients with abnormal pyruvate metabolism and a response to acetazolamide.
Topics: Acetazolamide; Adolescent; Adult; Ataxia; Female; Genes, Recessive; Humans; Lactates; Lactic Acid; M | 1984 |
Pyruvate-dehydrogenase complex in ataxic patients: enzyme deficiency in ataxic encephalopathy plus lactic acidosis and normal activity in Friedreich ataxia.
Topics: Acidosis; Adolescent; Ataxia; Brain Diseases; Fibroblasts; Friedreich Ataxia; Humans; Lactates; Lact | 1982 |
Normal activities of hepatic pyruvate dehydrogenase and pyruvate carboxylase in Leigh's syndrome.
Topics: Brain; Brain Stem; Central Nervous System Diseases; Encephalomalacia; Humans; Infant; Intellectual D | 1983 |
The post mortem diagnosis of fatal hypoglycaemia using the fatty liver and kidney syndrome of chicks as a model.
Topics: Animals; Biotin; Blood Glucose; Chickens; Fatty Liver; Glucose; Hypoglycemia; Kidney Diseases; Lacta | 1982 |
Netherton's syndrome.
Topics: Administration, Topical; Anti-Inflammatory Agents; Contraindications; Glucocorticoids; Humans; Ichth | 1995 |
Comparison of cardiopulmonary responses to forward and backward walking and running.
Topics: Athletic Injuries; Gait; Heart Rate; Humans; Knee Injuries; Lactates; Lactic Acid; Male; Oxygen Cons | 1994 |
High-dose adrenaline with low systemic vascular resistance and symmetrical peripheral gangrene.
Topics: Adult; Cardiac Output; Epinephrine; Gangrene; Humans; Hypotension; Lactic Acid; Malaria, Falciparum; | 1996 |
[The Ohtahara's syndrome: a special form of age-dependent epilepsy].
Topics: Adrenocorticotropic Hormone; Age of Onset; Ammonia; Brain; Electroencephalography; Epilepsy; Female; | 1997 |
Pearson's syndrome without marrow involvement.
Topics: Blotting, Southern; Bone Marrow; DNA, Mitochondrial; Female; Gene Deletion; Humans; Kidney Tubules; | 1997 |
Overtraining and glycogen depletion hypothesis.
Topics: Athletic Injuries; Bicycling; Dietary Carbohydrates; Energy Metabolism; Fatigue; Glycogen; Humans; H | 1998 |
Monitoring training in athletes with reference to overtraining syndrome.
Topics: Adult; Anaerobic Threshold; Athletic Injuries; Fatigue; Female; Heart Rate; Humans; Lactic Acid; Mal | 1998 |
Monitoring training in athletes with reference to overtraining syndrome.
Topics: Adult; Anaerobic Threshold; Athletic Injuries; Fatigue; Female; Heart Rate; Humans; Lactic Acid; Mal | 1998 |
Monitoring training in athletes with reference to overtraining syndrome.
Topics: Adult; Anaerobic Threshold; Athletic Injuries; Fatigue; Female; Heart Rate; Humans; Lactic Acid; Mal | 1998 |
Monitoring training in athletes with reference to overtraining syndrome.
Topics: Adult; Anaerobic Threshold; Athletic Injuries; Fatigue; Female; Heart Rate; Humans; Lactic Acid; Mal | 1998 |
Monitoring training in athletes with reference to overtraining syndrome.
Topics: Adult; Anaerobic Threshold; Athletic Injuries; Fatigue; Female; Heart Rate; Humans; Lactic Acid; Mal | 1998 |
Monitoring training in athletes with reference to overtraining syndrome.
Topics: Adult; Anaerobic Threshold; Athletic Injuries; Fatigue; Female; Heart Rate; Humans; Lactic Acid; Mal | 1998 |
Monitoring training in athletes with reference to overtraining syndrome.
Topics: Adult; Anaerobic Threshold; Athletic Injuries; Fatigue; Female; Heart Rate; Humans; Lactic Acid; Mal | 1998 |
Monitoring training in athletes with reference to overtraining syndrome.
Topics: Adult; Anaerobic Threshold; Athletic Injuries; Fatigue; Female; Heart Rate; Humans; Lactic Acid; Mal | 1998 |
Monitoring training in athletes with reference to overtraining syndrome.
Topics: Adult; Anaerobic Threshold; Athletic Injuries; Fatigue; Female; Heart Rate; Humans; Lactic Acid; Mal | 1998 |
Monitoring training in athletes with reference to overtraining syndrome.
Topics: Adult; Anaerobic Threshold; Athletic Injuries; Fatigue; Female; Heart Rate; Humans; Lactic Acid; Mal | 1998 |
Monitoring training in athletes with reference to overtraining syndrome.
Topics: Adult; Anaerobic Threshold; Athletic Injuries; Fatigue; Female; Heart Rate; Humans; Lactic Acid; Mal | 1998 |
Monitoring training in athletes with reference to overtraining syndrome.
Topics: Adult; Anaerobic Threshold; Athletic Injuries; Fatigue; Female; Heart Rate; Humans; Lactic Acid; Mal | 1998 |
Monitoring training in athletes with reference to overtraining syndrome.
Topics: Adult; Anaerobic Threshold; Athletic Injuries; Fatigue; Female; Heart Rate; Humans; Lactic Acid; Mal | 1998 |
Monitoring training in athletes with reference to overtraining syndrome.
Topics: Adult; Anaerobic Threshold; Athletic Injuries; Fatigue; Female; Heart Rate; Humans; Lactic Acid; Mal | 1998 |
Monitoring training in athletes with reference to overtraining syndrome.
Topics: Adult; Anaerobic Threshold; Athletic Injuries; Fatigue; Female; Heart Rate; Humans; Lactic Acid; Mal | 1998 |
Monitoring training in athletes with reference to overtraining syndrome.
Topics: Adult; Anaerobic Threshold; Athletic Injuries; Fatigue; Female; Heart Rate; Humans; Lactic Acid; Mal | 1998 |
Clinical spectrum of reversible posterior leukoencephalopathy syndrome.
Topics: Adolescent; Adult; Blood-Brain Barrier; Brain Edema; Child; Child, Preschool; Cyclosporine; Diagnosi | 2001 |
Hyperlactatemia syndromes in people with HIV infection.
Topics: Acidosis, Lactic; Anti-HIV Agents; Chemical and Drug Induced Liver Injury; HIV Infections; Homeostas | 2002 |
Osmolar gap hyponatremia in critically ill patients: evidence for the sick cell syndrome?
Topics: Amino Acids; Critical Illness; Female; Humans; Hyponatremia; Ketone Bodies; Lactic Acid; Male; Middl | 2002 |
Antiischemic and metabolic effects of glutamate during pacing in patients with stable angina pectoris secondary to either coronary artery disease or syndrome X.
Topics: Adult; Angina Pectoris; Cardiac Pacing, Artificial; Coronary Angiography; Coronary Disease; Electroc | 1991 |
Marked reduction in CSF lactate and pyruvate levels after CoQ therapy in a patient with mitochondrial myopathy, encephalopathy, lactic acidosis and stroke-like episodes (MELAS).
Topics: Acidosis, Lactic; Adult; Agnosia; Cerebrovascular Disorders; Delirium; Dose-Response Relationship, D | 1991 |
Therapeutic effect of sodium dichloroacetate on visual and auditory hallucinations in a patient with MELAS.
Topics: Acidosis, Lactic; Administration, Oral; Adult; Auditory Perception; Dichloroacetic Acid; Hallucinati | 1991 |
Therapeutic effects of a ketogenic diet in Rett syndrome.
Topics: Ammonia; Blood Glucose; Child; Child, Preschool; Dietary Fats; Electroencephalography; Energy Intake | 1986 |
Mitochondrial myopathy, encephalopathy, lactic acidosis and stroke-like episodes syndrome and NADH-CoQ reductase deficiency.
Topics: Acidosis; Adolescent; Cerebrovascular Disorders; Child, Preschool; Humans; Intellectual Disability; | 1986 |
Rett syndrome. A commonly overlooked progressive encephalopathy in girls.
Topics: Adolescent; Adult; Ataxia; Basal Ganglia Diseases; Brain Diseases; Child; Child, Preschool; Dementia | 1986 |
High plasma urea concentrations in collodion babies.
Topics: Betaine; Drug Combinations; Female; Humans; Ichthyosis; Infant, Newborn; Lactates; Lactic Acid; Skin | 1986 |
Chest pain and "normal" coronary arteries--role of small coronary arteries.
Topics: Adult; Blood Flow Velocity; Coronary Circulation; Coronary Vessels; Electrocardiography; Ergonovine; | 1985 |